Speechly Bircham has acted as the legal adviser to Elysian Capital on its acquisition, alongside the incumbent management team, of Accelyon Limited, a company specialising in brachytherapy, an important treatment option for early stage prostate cancer. Led by a highly experienced management team in the brachytherapy industry, it is expected that the company will quickly attain a market leading position in the delivery of brachytherapy, initially focussed on the UK and Ireland, Australia and New Zealand.
  
Edward Brett of Elysian Capital said "Accelyon came with an element of deal complexity across a number of overseas geographies, not least within its regulatory framework and its supply chain.  The Speechlys team brought a high level of commercialism and invaluable international reach.  We thoroughly enjoyed working with them on this investment opportunity."

Commenting on the transaction, Malcolm MacDougall, partner at Speechly Bircham, said: "We are delighted to have worked with Elysian Capital and Accelyon on the deal and to help develop this exciting business. Speechlys are very happy to have completed our first transaction for Elysian".

The Speechly Bircham team was led by private equity partner Malcolm MacDougall and private equity assistants Richard Coleman and Lee Holland, commercial contracts partner Mark Bailey and employment assistant Anne-Marie Balfour.

http://www.speechlys.com/news/news/current-news/2013/08/speechly-bircha…